Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rofecoxib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rofecoxib | DRUG | - |
| Comparator: placebo (unspecified) | DRUG | - |
Regular PSA testing and study biopsies required.
Top 20 of 53 competitors
Rofecoxib is an investigational small molecule being studied for the prevention of prostate cancer. It was evaluated in a Phase 3 clinical trial enrolling 15,000 male participants aged 50 years and older. The trial was completed, but rofecoxib is not approved and remains in clinical development.
Rofecoxib is being developed by Merck & Company, Inc., traded on the New York Stock Exchange under the ticker MRK. The company sponsored a Phase 3 clinical trial of rofecoxib for the prevention of prostate cancer.
Rofecoxib is in Phase 3 clinical development for the prevention of prostate cancer. One Phase 3 trial has been completed, and there are no active trials currently listed. Rofecoxib is investigational and has not been approved for this indication.
Rofecoxib was studied in a single completed Phase 3 trial, NCT00060476, titled "Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)." The trial enrolled 15,000 male participants aged 50 years and older and was randomized and double-blind.
Yes, rofecoxib is also known as MK0966. The clinical trial NCT00060476, which studied rofecoxib for prostate cancer prevention, refers to the drug as MK0966 in its title.